Back to top
more

2seventy bio, Inc. (TSVT)

(Delayed Data from NSDQ)

$4.40 USD

4.40
172,118

+0.06 (1.38%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $4.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

2seventy bio, Inc. (TSVT) Surges 28.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

2seventy bio, Inc. (TSVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up

by Zacks Equity Research

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

All You Need to Know About 2seventy bio, Inc. (TSVT) Rating Upgrade to Strong Buy

by Zacks Equity Research

2seventy bio, Inc. (TSVT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sanghamitra Saha headshot

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include DouYu International (DOYU), Regis (RGS), 2seventy bio Inc. (TSVT), atai Life Sciences (ATAI) and GameStop (GME).

Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study

by Zacks Equity Research

Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.

Bristol Myers (BMY) Partners With SystImmune for Oncology Drug

by Zacks Equity Research

Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.

Biotech Stock Roundup: BMY, TSVT Down on Setback, TRDA, MOR Offer Updates

by Zacks Equity Research

Regulatory setback for Bristol Myers (BMY) and other updates are in focus in the biotech sector.

Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback

by Zacks Equity Research

Bristol Myers Squibb (BMY) and 2seventy bio, Inc.'s efforts to seek approval for the label expansion of Abecma for earlier lines of treatment face a roadblock.

2seventy bio, Inc. (TSVT) Loses -44.63% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

2seventy bio, Inc. (TSVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

CRISPR Therapeutics AG (CRSP) Surges 12.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio, Inc. (TSVT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

2seventy bio, Inc. (TSVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

by Zacks Equity Research

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

Senti Biosciences, Inc. (SNTI) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Senti Biosciences, Inc. (SNTI) delivered earnings and revenue surprises of 12.50% and 27.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 65.85% and 164.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 20.69% and 0.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -44.87% and 8.67%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More

by Zacks Equity Research

Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.

2seventy (TSVT) Down 9% on Patient Death in Leukemia Study

by Zacks Equity Research

Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.

Legend (LEGN) Up 4% on sNDA Submission for Carvykti Expanded Use

by Zacks Equity Research

Legend (LEGN) announces regulatory submission for expanded use of Carvykti to include adult patients with relapsed and lenalidomide-refractory multiple myeloma. Stock rises 4% following the news.

2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 9.24% and 115.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK Gears Up to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

We expect GSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Bexsero, Shingrix and Juluca to drive first-quarter sales.

Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.

Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study

by Zacks Equity Research

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.